Armistice Capital’s Arbutus Biopharma ABUS Stock Holding History

Armistice Capital’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,600,000	Closed	-$5.2M	–	60
2017 Q1	$5.2M	Sell	1,600,000 -340,000	-18%	-$943K	1.07%	34
2016 Q4	$4.75M	Buy	1,940,000 +540,000	+39%	+$1.57M	1.12%	35
2016 Q3	$4.82M	Buy	1,400,000 +992,000	+243%	+$3.88M	1.55%	27
2016 Q2	$1.42M	Buy	+408,000	New	+$1.73M	0.54%	41

Other funds holding ABUS

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.36B AUM 25.58% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Armistice Capital's ABUS Position: Q2 2017 in Review

Armistice Capital sold out of Arbutus Biopharma (ABUS) in Q2 2017, closing a stake of 1,600,000 shares — an estimated $5.2M sold.

Armistice Capital first reported a position in ABUS in Q2 2016 and held it in 4 quarters. The position peaked at $5.2M in Q1 2017. 50 funds tracked by Wall St. Rank hold ABUS as of Q2 2017.

Armistice Capital reported no remaining Arbutus Biopharma position as of Q2 2017 after selling out during the quarter.
Armistice Capital sold 1,600,000 Arbutus Biopharma shares in Q2 2017, an estimated $5.2M.
Armistice Capital first reported a position in Arbutus Biopharma in Q2 2016 and held it in 4 quarters.
Armistice Capital's Arbutus Biopharma position peaked at $5.2M in Q1 2017.
50 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2017.

Based on Armistice Capital's 13F filing for Q2 2017, filed 14 Aug 2017.